Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07832837 in Healthy Participants and Participants With Moderate to Severe Atopic Dermatitis
NCT06564389Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2024
- Primary completion
- Jun 2027
- Modality
- Biologic
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing PF-07832837 with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Events and Serious Adverse Events at Day 80, Number of Participants with Clinically significant Laboratory Abnormalities at Day 80 and 3 more. Started Nov 2024; status: recruiting.
02
Drugs
PF-07832837
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06564389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564389.